Highlights Addex Therapeutics Ltd Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-28 EDT			5-day change	1st Jan Change
8.22 ^USD	+0.68%		+3.07%	+35.87%

06-06	Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024
06-06	Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	MT

Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	06-06	MT
European Equities Traded in the US as American Depositary Receipts Decline	04-30	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	04-29	MT
Sector Update: Health Care	04-29	MT
Top Midday Decliners	04-29	MT
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal	04-29	MT
Tech Rally Subsides as US Equity Futures Waver Pre-Bell	04-29	MT
Top Premarket Decliners	04-29	MT
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	04-29	DJ
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study	04-29	CI
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises	04-18	MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update	04-18	DJ
ADRs End Higher; Biophytis Climbs 30%	04-09	DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	04-09	MT
Top Premarket Gainers	04-09	MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	04-08	DJ
Top Premarket Gainers	04-03	MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders	04-03	CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders	04-03	DJ

No results for this search